Latest Pharma and Biotech News
Biotechnology
30 December 2024 Antibody-drug conjugates (ADCs) combine monoclonal antibody (MAb) specificity with cytotoxic drug potency via a linker, delivering targeted cancer therapy. ADCs concentrate treatment at tumor sites, enhancing efficacy while minimizing harm to healthy tissues.
Today's issue
Refine Search
Pharmaceutical
Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other. But one thing was clear – buyers were shying away from big bets on commercially ready medicines in favor of earlier stage drug developers. 3 January 2025
Pharmaceutical
Regeneron Pharmaceuticals has acquired UK-based biotech Oxular, enhancing its gene therapy development program with the firm’s specialized ocular delivery tech. 3 January 2025
Pharmaceutical
One of the most promising areas of medical innovation in the next five years is immuno-oncology (I-O)/cancer therapeutics represent, fundamentally transforming how cancer is treated. 3 January 2025
Pharmaceutical
Massachusetts, USA-based based brain disease biotech Neumora Therapeutics shares tumbled 81.4% to 1.97 after it revealed that its experimental depression treatment failed in the first of three studies planned by the biotech company. 3 January 2025
Pharmaceutical
Hutchmed has announced agreements to divest its 45% equity stake in Shanghai Hutchison Pharmaceuticals Limited (SHPL) for $608 million in cash. The buyers are GP Health Service Capital and Shanghai Pharmaceuticals. 2 January 2025
Pharmaceutical
Kazia Therapeutics, an oncology-focused Australian drug developer, has been advised by the US Food and Drug Administration (FDA) that accelerated approval for its brain cancer drug, paxalisib, is unlikely. 2 January 2025
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under the accelerated approval pathway for avutometinib, an oral RAF/MEK clamp, in combination with defactinib. 2 January 2025
Pharmaceutical
The new $2,000 cap on out-of-pocket costs for prescription drugs went into effect as of January 1, 2025, the US Department of Health and Human Services (HHS) Secretary Xavier Becerra has announced. 2 January 2025
Pharmaceutical
The market for artificial intelligence (AI) in cancer care is projected to grow from $2.2 billion in 2024 to $6.3 billion by 2029, reflecting a growth rate of 23.1%, according to a recent study by BCC Research. 31 December 2024
Pharmaceutical
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Winrevair (sotatercept) to treat pulmonary arterial hypertension (PAH), from US pharma giant Merck & Co. 31 December 2024
Pharmaceutical
US CNS specialist Axsome Therapeutics yesterday announced the completion of its Phase III clinical program evaluating AXS-05 (dextromethorphan-bupropion). 31 December 2024
Pharmaceutical
It has been a year since the launch of Zepbound (tirzepatide) for obesity, and US pharma major Eli Lilly’s competition with Denmark’s Novo Nordisk continues. 31 December 2024
Pharmaceutical
The US Food and Drug Administration (FDA) is reopening the comment period for the Federal Register notice (FRN), “Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-on Recombinant Peptide Products: Establishment of a Public Docket: Request for Information and Comments” due to high interest from industry. 31 December 2024
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has issued a warning urging the public to avoid purchasing weight-loss medicines without a prescription. 30 December 2024
Pharmaceutical
For many in the life sciences, the year gone by has been marked by volatility across a range of metrics, as political and economic disruptions threaten to upend the standard operating model. 30 December 2024
Pharmaceutical
China’s National Medical Products Administration (NMPA) has recently approved Zorifer (zorifertinib), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) specifically for the treatment of non-small cell lung cancer (NSCLC) with CNS metastases. 30 December 2024
Pharmaceutical
The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved the use of Hyqvia (immune globulin infusion 10% [human] with recombinant human hyaluronidase) in patients with agammaglobulinemia or hypogammaglobulinemia disorders, from domestic drug giant Takeda Pharma 27 December 2024
Pharmaceutical
Japanese drugmaker Kaken Pharmaceutical has entered into a license agreement with US healthcare giant Johnson & Johnson for the global development, manufacturing and commercialization of a STAT6 program that Kaken is developing. 27 December 2024
Pharmaceutical
Akums, India’s largest contract development and manufacturing organization (CDMO), has signed a strategic agreement with an undisclosed global pharmaceutical company. 27 December 2024
All news
Pharmaceutical
Johnson & Johnson, Genmab and Ono Pharmaceutical were among pharma's big spenders in M&A during April. 2 May 2024
Pharmaceutical
AstraZeneca has announced positive high-level results from an interim analysis of the ECHO Phase III trial. 2 May 2024
Pharmaceutical
Californian firm Daré Bioscience has completed a royalty monetization deal with XOMA, a company providing an alternative mechanism for biotechs to raise capital. 2 May 2024
Pharmaceutical
Pivotal data for the novel KRAS G12C inhibitor glecirasib have been presented at the April ASCO Plenary Series. 2 May 2024
Pharmaceutical
Danish diabetes giant Novo Nordisk today reported financial results for the first quarter of 2024, noting that sales increased by 22% in Danish kroner and by 24% at constant exchange rates to 65.3 billion kroner ($9.35 billion). 2 May 2024
Pharmaceutical
New Zealand-based AFT Pharmaceuticals has announced the licensing of Maxigesic IV, the intravenous form of its proprietary pain relief medicine, for Brazil. 2 May 2024
Pharmaceutical
At $14.9 billion, New York-based Pfizer has beaten estimates for first quarter revenues and raised its profit outlook accordingly. 1 May 2024
Pharmaceutical
Trade group the Association of the British Pharmaceutical Industry (ABPI) has published an executive summary of its consultation response to the government's proposed changes to the Statutory Scheme for branded medicines. 1 May 2024
Pharmaceutical
Shares in USA-based NRx Pharmaceuticals have fallen by around a fifth, after the firm announced disappointing results from a trial of NRX-101. 1 May 2024
Pharmaceutical
UK pharma major GSK today reported first quarter 2024 financial results, showing that total sales were £7.4 billion ($9.26 billion) +10% and +13% ex COVID revenues. 1 May 2024
Pharmaceutical
Neurocrine Biosciences has secured US Food and Drug Administration approval for Ingrezza Sprinkle (valbenazine). 1 May 2024
Pharmaceutical
The USA’s Federal Trade Commission yesterday revealed it has expanded its campaign against pharmaceutical manufacturers’ improper or inaccurate listing of patents in the Food and Drug Administration’s (FDA) Orange Book, disputing junk patent listings for diabetes, weight loss, asthma and COPD drugs. 1 May 2024
Pharmaceutical
US pharma giant Merck & Co has announced results from STRIDE-10, a Phase III trial of V116, the company’s investigational, adult-specific 21-valent pneumococcal conjugate vaccine (PCV), at the European Society of Clinical Microbiology and Infectious Diseases event in Barcelona, Spain. 30 April 2024
Pharmaceutical
Shares of US developer of rare neurological drugs Harmony Biosciences (Nasdaq: HRMY) rose more than 10% to $32.30 today, after it announced the acquisition of Epygenix Therapeutics. 30 April 2024
Pharmaceutical
Oncotelic Therapeutics has agreed to sell to Mosaic ImmunoEngineering rights to its clinical-stage necroptosis cancer therapies. 30 April 2024
Pharmaceutical
US pharma major Eli Lilly today announced its financial results for the first quarter of 2024 and raised it guidance, with the news pushing the firm’s share up 5.6% to $778.19. 30 April 2024
Pharmaceutical
X4 Pharmaceuticals has secured US approval for Xolremdi (mavorixafor), for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis). 30 April 2024
Pharmaceutical
A full cycle of production of a drug for the treatment of Fabry disease will be launched in Russia this year, reports The Pharma Letter’s local correspondent. 30 April 2024
Pharmaceutical
A once-weekly insulin product developed by Novo Nordisk will be reviewed by an advisory panel, convened by the US regulator, on 24 May. 30 April 2024
Pharmaceutical
Italy-based biopharma Newron Pharmaceuticals was trading 14% higher at lunchtime on Tuesday. 30 April 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze